Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

Zealand Pharma's stock fell 11.7% after its partner Boehringer Ingelheim released Phase III trial results for survodutide. The drug met its primary endpoints, but 18% of patients discontinued due to gastrointestinal side effects. Investors are concerned about the drug's differentiation in the competitive obesity market, impacting Zealand's future revenues.

Zealand Pharma (ZEAL.CO) reported Phase 3 trial results for Survodutide, a weight-loss drug licensed to Boehringer Ingelheim. The trial showed up to 13.1% weight loss vs. 3.1% for placebo, with 79.3% achieving 5%+ weight loss. HbA1c and waist circumference also improved. GI side effects were common. Boehringer plans further trials. ZEAL.CO shares fell 10.37%.

Zealand Pharma's shares dropped 12.5% after a Phase III trial of its obesity drug survodutide showed significant weight loss in type 2 diabetes patients, but 18% discontinued due to gastrointestinal side effects. The trial met its main goals, with patients losing up to 13.1% body weight. The drug is licensed to Boehringer Ingelheim, which is responsible for its development and commercialization.

Zealand Pharma reported that Boehringer Ingelheim's survodutide achieved co-primary endpoints in its Phase III trial, with participants experiencing up to 13.1% weight loss compared to 3.1% for placebo over 76 weeks. The drug also improved glycemic control in adults with obesity or type 2 diabetes, according to the company.

Zealand Pharma (ZEAL.CO) announced a positive EU opinion for Zeydovio (glepaglutide) in treating short bowel syndrome, based on Phase 3 trial data. The CHMP recommendation, supported by significant trial results, awaits European Commission approval. The company is also advancing a U.S. trial for potential FDA submission.

Royalty Pharma (RPRX) agreed to a $100M deal with Zealand Pharma for rights to a rare blood disorder therapy. RPRX shares are down 1.86% to $60.58, but up 11.16% over 90 days and 70.08% over a year. Analysts debate its valuation, with some calling it 2% overvalued at $59.25, while a DCF model suggests it's heavily discounted at $195.31.